Advanced Search

Subscribe to a Global-Regulation Premium Membership Today!

We are constantly working to improve the site, and to add more laws to our database. If you are receiving value from using our site please consider signing up for a subscription to support the site and to get many additional benefits for you.

Key Benefits:

  • Unlimited Searches
  • Weekly Updates on New Laws
  • Access to 5,345,848 Global Laws from 110 Countries
  • View the Original Law Side-by-Side with the Translation
  • No Ads

Subscribe Now for only USD$40 per month.

(You can close this ad by clicking anywhere on the page.)

National Health Determination under paragraph 98C(1)(b) Amendment 2015 (No. 4) (PB 41 of 2015)

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
PB 41 of 2015
 
National Health Determination under paragraph 98C(1)(b) Amendment 2015
(No. 4)
_____________________________________________________________________
 
 
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1)(b) of the National Health Act 1953.
 
Dated 22 April 2015
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health
 
 
 
1              Name of Instrument
(1)                This Instrument is the National Health Determination under paragraph 98C(1)(b) Amendment 2015 (No. 4).
(2)                This Instrument may also be cited as PB 41 of 2015.
2              Commencement                                                        
                This instrument commences on 1 May 2015.
3              Amendments to Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)
                Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).
Schedule 1            Amendments
 
[1]           Schedule 4, after entry for Latanoprost with Timolol
insert:
Leuprorelin
I.M. injection (3 month modified release), powder for injection containing leuprorelin acetate 30 mg with diluent in pre-filled dual-chamber syringe
[2]           Schedule 4, entry for Oestradiol
omit:
 
Vaginal tablets 25 micrograms, 15